Stock STIM NEURONETICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Neuronetics, Inc.

Equities

STIM

US64131A1051

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
3.75 USD -2.85% Intraday chart for Neuronetics, Inc. -5.30% +29.31%
Apr. 10 Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation CI
Mar. 28 Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
AQ
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
GL
Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation
CI
Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board
CI
Neuronetics Reports Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
AQ
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21
DJ
Neuronetics Gets US FDA Clearance for Treatment of Adolescents with Depression; Shares Rise
MT
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
GL
Neuronetics, Inc. Announces Clearance from the U.S. Food and Drug Administration for NeuroStar Advanced Therapy
CI
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
GL
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
AQ
Neuronetics, Inc. Announces 5-Year Exclusive Partnership with Transformations Care Network
CI
Neuronetics : STIM Corporate Presentation March 2024
PU
Transcript : Neuronetics, Inc., Q4 2023 Earnings Call, Mar 05, 2024
Neuronetics: Q4 Earnings Snapshot
AQ
Earnings Flash (STIM) NEURONETICS Reports Q4 Revenue $20.3M
MT
Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results
AQ
Neuronetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. STIM Stock
  4. News Neuronetics, Inc.